07:00 , May 16, 2005 |  BioCentury  |  Finance

IPO angst in Europe

The European IPO market has sent mixed signals over the past two weeks about whether it's open or closed. Red flags were raised by Speedel Group pulling the plug on its proposed deal and by...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

EP-1572: Phase I data

Data from an open-label, placebo-controlled, dose-escalation, Swiss Phase I trial in 36 healthy male volunteers showed that EP-1572 induced increased levels of growth hormone in blood within 1-2 hours of treatment without any affect on...
07:00 , Apr 4, 2005 |  BioCentury  |  Finance

2Q Financial Market Preview: Steady but unsatisfying

The duration of biotech financing windows historically has been capped at 20 months. The current window is at 21 months, but there’s reason to believe that it can stay open for longer, especially for companies...
08:00 , Feb 21, 2005 |  BC Week In Review  |  Clinical News

Teverelix LA: Phase IIa data

Data from a European Phase IIa trial in the first set of 14 patients showed that in 93% of patients Teverelix LA led to a reduction in testosterone levels equivalent to those of castrated men...
08:00 , Feb 7, 2005 |  BC Week In Review  |  Company News

Ardana Bioscience, U.K. Medical Research Council deal

Ardana extended for three years its exclusive option to commercialize selected research conducted by the MRC's Human Reproductive Sciences Unit. The original deal began in 2000 and had a five-year term. Ardana Bioscience Ltd. ,...
08:00 , Nov 1, 2004 |  BC Week In Review  |  Clinical News

Striant SR testosterone regulatory update

CBRX completed the European Mutual Recognition Procedure for Striant SR 30 mg testosterone buccal product to treat male hypogonadism. The U.K. acted as reference member state. The product will be marketed in 18 European countries...
07:00 , Aug 9, 2004 |  BC Week In Review  |  Clinical News

Striant testosterone: Phase III data

Previously reported results from an open-label, U.S. Phase III trial in 98 patients showed 86.6% of patients had an average testosterone concentration within the physiologic range at the end of 12 weeks (see BioCentury, June...
07:00 , Aug 9, 2004 |  BC Week In Review  |  Company News

Ardana Bioscience management update

Ardana Bioscience Ltd. , Edinburgh, U.K.   Business: Genitourinary   Hired: Time Morley as VP of preclinical sciences, formerly senior director of molecular and cellular pharmacology at Vernalis Research Ltd.  ...
07:00 , Jul 5, 2004 |  BC Week In Review  |  Clinical News

Striant SR regulatory update

CBRX applied for European marketing authorization under the Mutual Recognition Procedure for its Striant SR testosterone buccal product to treat male hypogonadism. In February, Striant was approved in the U.K., the reference member state. Upon...
07:00 , Jun 7, 2004 |  BC Week In Review  |  Company News

Ardana Bioscience, Columbia sales and marketing update

Ardana launched CBRX's Striant SR buccal testosterone system in the U.K. to treat hypogonadism. Ardana has U.K. and European commercialization rights to the compound. Ardana Bioscience Ltd. , Edinburgh, U.K.   Columbia Laboratories Inc. (CBRX),...